固形腫瘍の治療における抗LAG-3と抗PD-1の併用および非併用の安全性、忍容性および有効性を評価するための治験的免疫療法研究

基本情報

NCT ID

NCT01968109

ステータス

完了

試験のフェーズ

第1/第2相

試験タイプ

介入

目標被験者数

1,482

治験依頼者名

Bristol-Myers Squibb

概要

The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery. The following tumor types are included in this study: Non-Small Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, squamous cell carcinoma of the head and neck, and melanoma, that have NOT previously been treated with immunotherapy. NSCLC and melanoma that HAVE previously been treated with immunotherapy.

対象疾患

介入

依頼者（Sponsor）